Trial Information

Summary: A Phase I Dose Escalation Study of Peptide Vaccines with Activity Against Human Cytomegalovirus

You have been asked to take part in this research study because you are a healthy adult who may be eligible for a study about vaccines for human cytomegalovirus (CMV) or because you were in study protocol #97092.  The purpose of this study is to find out the safety and the best dose of two types of CMV vaccines, alone or with something added, called CPG 7909 for Injection (CPG 7909).  Your participation in this study will last up to 12 months. 

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:39:57 PM